David Miklos, MD, associate professor of medicine, Blood and Marrow Transplantation, and clinical director of Cancer Cell Therapy at Stanford University Medical Center, discusses the process of developing KTE-X19 and the ZUMA-2 trial in mantle cell lymphoma.
Website: onclive.com
Twitter: twitter.com/OncLive
Facebook: facebook.com/OncLive/
LinkedIn: linkedin.com/company/onclive
- Dr. Miklos on Development Process for KTE-X19 in MCL ( Download)
- Dr. Miklos on the Safety Profile of KTE-X19 in MCL ( Download)
- Dr. Miklos on Anticipated Sequencing Challenges With KTE-X19 in MCL ( Download)
- Dr. Miklos on Alternative Options to KTE-X19 in MCL, While Awaiting FDA Decision ( Download)
- Dr. Wang on the Safety Profile of KTE-X19 in MCL ( Download)
- Dr. Miklos on the Results of the ZUMA-2 Trial in MCL ( Download)
- Dr. Wang on Unique Properties of KTE-X19 in Relapsed/Refractory MCL ( Download)
- Dr. Wang on the Evolution of Treatment in MCL ( Download)
- Dr. Goy on the Evolution of Treatment Selection in MCL ( Download)
- Dr. Smith on Safety Profiles of BTK Inhibitors in MCL ( Download)
- Dr. Zelenetz on Progress Made in MCL Treatment ( Download)
- Developments in CAR T treatments for adult patients ( Download)
- CAR T cell Options for Relapsed/Refractory DLBCL ( Download)
- Lymphoma, Leukemia, Multiple Myeloma: Clinical Trials, CAR T & More | Dr. David Miklos, Stanford ( Download)
- Dr. Goy on Research Efforts With BTK Inhibitors in MCL ( Download)
